Caribou Biosciences Inc
CRBU
NASDAQ
Biotechnology
$1.58
USD
-0.03 (-1.86%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $159.68M
Volume 1.2M
Revenue
$11.20M
TTM
+13.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-133.22M
TTM
+9.9%
YoY
Operating Cash Flow
$-101.25M
TTM
+26.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 2.4 | 2.7 | 2.2 | 3.9 | 2.4 |
YoY Growth | -3.1% | -23.0% | +8.6% | +89.7% | +1.9% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 2.4 | 2.7 | 2.2 | 3.9 | 2.4 |
Selling, General & Administrative | 9.7 | 10.4 | 9.2 | 8.6 | 8.1 |
Other Operating Expenses | 0.0 | 12.2 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 45.3 | 50.2 | 31.6 | 32.4 | 28.7 |
Operating Income | -42.9 | -47.6 | -29.4 | -28.5 | -26.3 |
EBITDA | -41.7 | -34.3 | -28.8 | -27.8 | -25.6 |
Other Income / Expense | 2.9 | -6.5 | 1.9 | 1.4 | 1.2 |
Total Other Income / Expense | 2.9 | -6.5 | 1.9 | 1.4 | 1.2 |
Income Before Income Taxes | -40.0 | -54.1 | -27.5 | -27.0 | -25.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.6 | 0.0 |
Net Income | -40.0 | -54.1 | -27.5 | -26.5 | -25.1 |
Consolidated Net Income / Loss | -40.0 | -54.1 | -27.5 | -26.5 | -25.1 |
Net Income Attributable to Common Shareholders | -40.0 | -54.1 | -27.5 | -26.6 | -25.1 |
Basic EPS | -$0.43 | -$0.58 | -$0.30 | -$0.28 | -$0.26 |
Diluted EPS | -$0.43 | -$0.58 | -$0.30 | -$0.28 | -$0.26 |
Basic Shares Outstanding | 92.7M | 93.0M | 93.3M | 94.6M | 95.9M |
Diluted Shares Outstanding | 92.7M | 93.0M | 93.3M | 94.6M | 95.9M |